The role of nitric oxide in atherosclerosis

Coronary Artery Disease

Volumn 10, Issue 5, 1999, Pages 277-286

  Maxwell, Andrew J ^b   Cooke, John P ^a  

^a STANFORD UNIVERSITY   (United States)

^b Division of Research and Development   (United States)

Author keywords

Asymmetric dimethylarginine; Coronary artery disease; Endothelium derived nitric oxide; Nitric oxide synthase

Indexed keywords

ARGININE; FREE RADICAL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CORONARY ARTERY DISEASE; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032772664     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199907000-00002     Document Type: Review

References (117)

1. 1 National Center for Health Statistics. Annual summary of births, marriages, divorces and deaths, United States 1994. Monthly Vital Statistics Report 1995. 1994; 43:13.
2. 2 Morano MA. Current estimates from the National Health Interview Survey, 1994. In: National Center for Health Statistics, ed. DHSS publication PHS 96-1521. Washington DC: US Government Printing Office; 1996.
3. 3 Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88:2149-2155. This study conducted in 80 current smokers, 40 former smokers and 80 control subjects, showed that endothelium-dependent flow-mediated vasodilation was inversely related to lifetime dose smoked. Abnormal flow-mediated vasodilation was shown to be potentially reversible.
4. 4 Lüscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 1987; 9:157-163.
5. 5 Wu G, Meininger CJ. Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am J Physiol 1995; 269:H1312-H1318.
6. 6 Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996; 27:978-990.
7. 7 Ockene JK, Kuller LH, Svendsen KH, Meilahn E. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Pubic Health 1990; 80:954-958.
8. 8 Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313:1511-1514. This case-control study of over 4500 men demonstrated that the relative risk of non-fatal myocardial infarction from smoking returns to the same level as that of non-smokers after about 2 years.
9. 9 Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995; 346:467-471.
10. 10 Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487. This double-blind, placebo-controlled study demonstrated that cholesterol lowering with lovastatin improves endothelial function, at least after 6 months of therapy.
11. 11 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009. This double-blind, placebo-controlled trial of over 4000 individuals with CAD and average cholesterol levels (< 240 mg/dl) demonstrated a benefit (24% reduction in risk of fatal coronary event) of cholesterol-lowering therapy in patients with CAD who have otherwise average cholesterol levels.
12. 12 Fuster V, Gotto AM, Libby P, Loscalzo J, McGill HC: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol 1996; 27:964-976. Definitive review of the pathogenesis of CAD and the biological basis of individual risk factors.
13. 13 Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251:788-791.
14. 14 Ross R. Cellular and molecular studies of atherogenesis. Atherosclerosis 1997; 131 (suppl):S3-S4.
15. 15 Tsao PS, Lewis NP, Cooke JP. Exposure to shear stress alters endothelial adhesiveness: role of nitric oxide. Circulation 1995; 92:3513-3519.
16. 16 Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995; 76:980-986.
17. 17 Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96:934-940.
18. 18 Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996; 94:1682-1689.
19. 19 Garg UC, Hassid A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun 1990; 171:474-479.
20. 20 DeCaterina R, Libby P, Peng H-B, Thannickal VJ, Rajavashisth TB, Gimbrone MAJ, et al. Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest 1995; 96:60-68.
21. 21 McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991; 84:1273-1278.
22. 22 Ohara Y, Petersen TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91:2546-2551.
23. 23 Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92:1866-1874.
24. 24 Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270:14214-14219.
25. 25 Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991; 266:4244-4250.
26. 26 Stamler JS, Simon DI, Osborne JA, Mullins M, Jaraki O, Michel T, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992; 89:444-448.
27. 27 Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993; 334:170-174.
28. 28 Clancy RM, Leszczynska P, Piziak J, Abramson SB. Nitric oxide, an endothelial cell relation factor, inhibits neutrophil superoxide anion production via a direct action of NADPH oxidase. J Clin Invest 1992; 90:1116-1121.
29. 29 Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29:479-485.
30. 30 Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
31. 31 Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995; 25:201-206.
32. 32 Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994; 23:1610-1616.
33. 33 Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 199; 20 (suppl 12):S60-S62.
34. 34 Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842-1847.
35. 35 Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95:2068-2074. This case-control study demonstrated the progressive reduction in NOS activity (as measured by urinary nitrate and cGMP excretion) and severity of peripheral arterial disease. The study demonstrated the usefulness of measuring urinary products as a clinical tool in measuring NO activity.
36. 36 Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269:H1522-H1527.
37. G dimethylarginine by human endothelial cells. Endothelium 1993; 1:137-140.
38. 38 Weidinger F, McLenachan JM, Cybulsky MI, Gordon JB, Rennke HG. Hollenberg NK, et al. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 1990; 81:1667-1679.
39. 39 Shimokawa H, Lawrence LA, Vanhoutte PM. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 1987; 61:256-259.
40. 40 MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119:1-8.
41. 41 Rawal N, Rajpurohit R, Lischwe MA, Williams KR, Paik WK, Kim S. Structural specificity of substrate for s-adenosylmethionine : protein arginine N-methyltransferases. Biochim Biophys Acta 1995; 1248:11-18.
42. 42 MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112:43-48.
43. 43 Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77:510-518.
44. 44 Huk I, Nanobashvili J, Neumayer C, Punz A, Mueller A, Afkhampour K, et al. L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation 1997; 96:667-675.
45. 45 Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995; 91:139-144.
46. 2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992; 281:627-630.
47. 47 Mayer B, John M, Heinzel B, Werner ER, Wachter H, Schultz G, et al. Brain nitric oxide synthase is a biopterin-and flavin-containing multi-functional oxido-reductase. FEBS Lett 1991; 288:187-191.
48. 48 Grisham MB, McCord J. Chemistry and cytotoxicity of reactive oxygen metabolites. In: Taylor AE, Matalon S, Ward P (editors): Physiology of oxygen radicals. Bethesda, MD: American Physiologic Society; 1986. pp. 1-18.
49. 49 Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77:1370-1376.
50. 50 Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731-741.
51. 51 Stamler JS, Osborne JA, Jaraki O, Rabbani E, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-318.
52. 52 McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22:215-227. An early presentation of the hypothesis that elevated levels of homocysteine accelerated atherosclerosis.
53. 53 Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996; 28:419-426.
54. 54 Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997; 40:156-164.
55. 55 Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45 (suppl 3):S77-S80.
56. 56 Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997; 46:1481-1490.
57. 57 Hornig B, Arakawa N, Smolarski R, Schieffer B, Drexler H. Concomitant enhancement of NO-mediated vasodilation and pro-fibrinolytic activity by ACE-inhibition in patients with coronary artery disease. Circulation 1997; 96:1114.
58. 58 Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
59. 59 Miller VM, Burnett JC Jr. Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol 1992; 263:H103-H108.
60. 60 Niebauer J, Cooke JP. Cardiovascular effects of exercise: role of endothelial shear stress. J Am Coll Cardiol 1996; 28:1652-1660.
61. 61 Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994; 74:349-353. This study was the first to demonstrate the inducible nature of constitutive NOS. Chronic exercise can stimulate endothelial cell NOS gene expression.
62. 62 Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990; 67:1301-1308.
63. 63 Cooke JP, Dzau J, Creager A. Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. Basic Res Cardiol 1991; 86 (suppl 2):173-181.
64. 64 Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90:1168-1172.
65. 65 Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97:1989-1994. This randomized, double-blind, crossover study demonstrated the effectiveness of oral L-arginine (21 g/day) in restoring endothelial function (as measured by flow-mediated vasodilation of the brachial artery by high resolution ultrasound).
66. 66 Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88:10480-10484. This work characterized the endothelial cell NOS enzyme, including its Michaelis-Menten constant. Results from this work helped to create the controversy over the utility of providing excess L-arginine to enhance EDNO activity. This controversy became known as the 'Arginine Paradox'.
67. 67 Wang BY, Singer AH, Tsao PS, Drexler H, Kosek J, Cooke JP. Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J Am Coll Cardiol 1994; 23:452-458.
68. 68 Aji W, Ravalli S, Szabolcs M, Jiang XC, Sciacca RR, Michler RE, et al. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 1997; 95:430-437.
69. 69 Böger RH, Bode-Böger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96:1282-1290. This study confirmed earlier work which showed that L-arginine can inhibit the progression of atherosclerotic lesion formation in experimental hypercholesterolemia. In this study, L-arginine was more effective than lovastatin at inhibiting the progression of atherosclerosis. In addition, L-arginine inhibited, while lovastatin potentiated superoxide radical generation.
70. 70 Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 1996; 16:44-50.
71. 71 Wang B, Lin PS, Tsao PS, Cooke JP. Nitric oxide induces regression: role of apoptosis. Circulation 1996; 94:A900.
72. 72 Lin KT, Xue JY, Nomen M, Spur B, Won PY. Peroxynitrite-induced apoptosis in HL-60 cells. J Biol Chem 1995; 270:16487-16490.
73. 73 McVeigh GE, Lemay L, Morgan D, Cohn JN. Effects of long-term cigarette smoking on endothelium-dependent responses in humans. Am J Cardiol 1996; 78:668-672.
74. 74 Kugiyama K, Yasue H, Ohgushi M, Motoyama T, Kawano H, Inobe Y, et al. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol 1996; 28:1161-1167.
75. 75 Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997; 29:491-497.
76. 76 Pieper GM, Siebeneich W, Dondlinger LA. Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Eur J Pharmacol 1996; 317:317-320.
77. 77 Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992; 89:11259-11263.
78. 78 Tagawa H, Tagawa T, Shimokawa H. Estrogen acutely improves nitric-oxide mediated and non-nitric oxide mediated endothelium-dependent vasodilation in postmenopausal women. Circulation 1995; 92:168.
79. 79 Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991; 265:627-631.
80. 80 Reis SE. Oestrogens attenuate abnormal coronary vasoreactivity in postmenopausal women. Ann Med 1994; 26:387-388.
81. 81 Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121:936-941.
82. 82 McCrohon JA, Walters WA, Robinson JT, McCredie RJ, Turner L, Adams MR, et al. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 1997; 29:1432-1436.
83. 83 New G, Timmins KL, Duffy SJ, Tran BT, O'Brien RC, Harper RW, et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997; 29:1437-1444.
84. 84 Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM. et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation 1987; 75:1102-1109.
85. 85 Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20:47-63.
86. 86 Knight DC, Eden JA. A review of the clinical efforts of phytoestrogens. Obstet Gynecol 1996; 87:897-904.
87. 87 Meeker DR, Kesten HD: Effects of high protein diets on experimental atherosclerosis of rabbits. Arch Pathol 1941; 31:147-162.
88. 88 Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99:41-46.
89. 89 Schaffner A, Blau N, Schneemann M, Steurer J, Edgell CJ, Schoedon G. Tetrahydrobiopterin as another EDRF in man. Biochem Biophys Res Commun 1994; 205:516-523.
90. 90 Hennig B, McClain CJ, Diana JN. Function of vitamin E and zinc in maintaining endothelial integrity. Implications in atherosclerosis. Ann NY Acad Sci 1993; 686:99-109; discussion 109-111.
91. 91 Vitoux D, Chappuis P, Arnaud J, Bost M, Accominotti M, Roussel AM. Selenium, glutathione peroxidase, peroxides and platelet functions. Ann Biol Clin (Paris) 1996; 54:181-187.
92. 92 Princen HM, van Duyvenvoorde W, Buytenhek R, van der Laarse A, van Poppel G, Gevers Leuven JA, et al. Supplementation with low doses of vitamin E protects LDL from lipid poroxidation in men and women. Arterioscler Thromb Vasc Biol 1995; 15:325-333.
93. 93 Matz J, Andersson TL, Ferns GA, Anggard EE. Dietary vitamin E increases the resistance to lipoprotein oxidation and attenuates endothelial dysfunction in the cholesterol-fed rabbit. Atherosclerosis 1994; 110:241-249.
94. 94 Mosca L, Rubenfire M, Mandel C, Rock C, Tarshis T, Tsai A, et al. Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. J Am Coll Cardiol 1997; 30:392-399.
95. 95 Martin A, Wu D, Bauer W, Meydani SN, Blumberg JB, Meydani M. Effect of vitamin E on human aortic endothelial cell responses to oxidative injury. Free Radic Biol Med 1996; 21:505-511.
96. 96 Haendeler J, Zeiher AM, Dimmler S. Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Eur J Pharmacol 1996; 317:407-411.
97. 97 Andersson TL, Matz J, Ferns GA, Anggard EE. Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis 1994; 111:39-45.
98. 98 Stewart-Lee AL, Forster LA, Nourooz-Zadeh J, Ferns GA, Anggard EE. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscler Thromb 1994; 14:494-499.
99. 99 Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95:2617-2622.
100. 100 Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93:1107-1113.
101. 101 Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996; 94:6-9.
102. 102 Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin c improves endothelium-dependent vasodilation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996; 97:22-28.
103. 103 Plotnick GD, Corretti MC, Vogel RA. Effects of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997; 278:1682-1686.
104. 104 Gilligan DM, Sack MN, Guetta V, Casino PR, Quyyumi AA, Rader DJ, et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hyperchoesterolemia. J Am Coll Cardiol 1994; 24:1611-1617.
105. 105 Elliott TG, Barth JD, Mancini GB. Effects of vitamin E on endothelial function in men after myocardial infarction. Am J Cardiol 1995; 76:1188-1190.
106. 106 Green D, O'Driscoll G, Blanksby B, Taylor R. Lack of effect of vitamin E administration on basal nitric oxide function in male smokers and non-smokers. Clin Sci 1995; 89:343-348.
107. 107 Hodis HN, Mack WJ, LaBree L, Cashin-Hemphill L, Sevanian A, Johnson R, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273:1849-1854. This non-randomized, placebo-controlled trial demonstrated that dietary supplementation with vitamins E (but not vitamin C) inhibited coronary artery lesion progression (as measured by angiography) in persons who had previously undergone coronary artery bypass graft surgery.
108. 108 Kritchevsky SB, Shimakawa T, Tell GS, Dennis B, Carpenter M, Eckfeldt JH, et al. Dietary antioxidants and carotid artery wall thickness. The ARIC (Atherosclerosis Risk in Communities) study. Circulation 1995; 92:2142-2150.
109. 109 Losoncy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr 1996; 64:190-196.
110. 110 Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 322:488-493.
111. 111 Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25:176-181.
112. 112 Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Genet 1996; 58:17-20.
113. 113 Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorenson KE, Adams M, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28:573-579.
114. 114 Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci 1996; 91:567-573.
115. 115 Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263:H321-H326.
116. 116 Marfella R, Acampora R, Verrazzo G, Ziccardi P, De Rosa N, Giunta R, et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 1996; 19:934-939.
117. 117 Kilo C. Metformin: a safe and effective treatment in the management of NIDDM. Mo Med 1997; 94:114-123.